Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)

被引：0
|
作者：
Stelljes, Matthias
Su, Yun
Fahrbach, Kyle
Vandendries, Erik
Page, Veronique
Onyekwere, Uchenna
Wang, Yunyang
Cappelleri, Joseph C.
Proskorovsky, Irina
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2558
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO).
    Krueger, Joerg
    Bittencourt, Henrique N. S.
    Rives, Susana
    Baruchel, Andre
    De Moerloose, Barbara
    Peters, Christina
    Bader, Peter
    Buechner, Jochen
    Boissel, Nicolas
    Hiramatsu, Hidefumi
    Thudium, Karen
    Sanjeevi, Prasanthi
    White, Marina
    Eldjerou, Lamis K.
    Balduzzi, Adriana
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [12] WEEKLY INOTUZUMAB OZOGAMICIN (INO) IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    DeAngelo, D. J.
    Stock, W.
    Shustov, A. R.
    Ananthakrishnan, R.
    Luu, K.
    Boni, J.
    Volkert, A.
    Vandendries, E.
    Advani, A. S.
    HAEMATOLOGICA, 2013, 98 : 463 - 464
  • [13] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
    Bhojwani, Deepa
    Sposto, Richard
    Shah, Nirali N.
    Rodriguez, Vilmarie
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    O'Brien, Maureen M.
    McNeer, Jennifer L.
    Quereshi, Amrana
    Cabannes, Aurelie
    Schlegel, Paul
    Rossig, Claudia
    Dalla-Pozza, Luciano
    August, Keith
    Alexander, Sarah
    Bourquin, Jean-Pierre
    Zwaan, Michel
    Raetz, Elizabeth A.
    Loh, Mignon L.
    Rheingold, Susan R.
    LEUKEMIA, 2019, 33 (04) : 884 - 892
  • [14] Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
    Ueda, Tomoaki
    Fukushima, Kentaro
    Kusakabe, Shinsuke
    Yoshida, Koki
    Suga, Makiko
    Nakai, Ritsuko
    Koike, Midori
    Hino, Akihisa
    Akuta, Keigo
    Toda, Jun
    Nagate, Yasuhiro
    Doi, Yukiko
    Fujita, Jiro
    Yokota, Takafumi
    Hosen, Naoki
    LEUKEMIA RESEARCH REPORTS, 2022, 17
  • [15] Indirect treatment comparison of blinatumomab versus inotuzumab ozogamicin for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia receiving zero or one prior salvage therapy.
    Song, Jinlin
    Ma, Qiufei
    Gao, Wei
    Cong, Ze
    Xie, Jipan
    Zimmerman, Zachary Franklin
    Belton, Laura
    Franklin, Janet
    Palmer, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [16] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
    Deepa Bhojwani
    Richard Sposto
    Nirali N. Shah
    Vilmarie Rodriguez
    Constance Yuan
    Maryalice Stetler-Stevenson
    Maureen M. O’Brien
    Jennifer L. McNeer
    Amrana Quereshi
    Aurelie Cabannes
    Paul Schlegel
    Claudia Rossig
    Luciano Dalla-Pozza
    Keith August
    Sarah Alexander
    Jean-Pierre Bourquin
    Michel Zwaan
    Elizabeth A. Raetz
    Mignon L. Loh
    Susan R. Rheingold
    Leukemia, 2019, 33 : 884 - 892
  • [17] Inotuzumab Ozogamicin (Besponsa®) for Patients with relapsed or refractory acute lymphoblastic Leukemia (r/r ALL)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 66 - 66
  • [18] Characteristics of Medicare patients with relapsed/refractory acute lymphoblastic leukemia initiating treatment with inotuzumab ozogamicin, blinatumomab, or other agents.
    Russell-Smith, T. Alexander
    Shah, Richa
    Silverstein, Alison R.
    Petrilla, Allison A.
    Leinwand, Brian
    Norris, Diane
    Schroeder, Amy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E19009 - E19009
  • [19] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
    Bhojwani, Deepa
    Sposto, Richard
    Shah, Nirali
    Rodriguez, Vilmarie
    O'Brien, Maureen Megan
    McNeer, Jennifer Lynn
    Loh, Mignon L.
    Rheingold, Susan R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [20] Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
    Verneris, Michael R.
    Ma, Qiufei
    Zhang, Jie
    Keating, Amy
    Tiwari, Ranjan
    Li, Junlong
    Yang, Hongbo
    Agarwal, Abhijit
    Pacaud, Lida
    BLOOD ADVANCES, 2021, 5 (23) : 5387 - 5395
12345